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An MTHFR variant, homocysteine, and cardiovascular comor- and epidemiologic evidence is mixed, and the lack of clini-
bidity in renal disease. cal trials leaves the question of causality open. There is
Background. It is unclear whether total serum homocysteine less evidence concerning the relationship between total
(tHcy) and the C677T mutation of methylenetetrahydrofolate
serum homocysteine (tHcy) [1] and cardiovascular risk inreductase (MTHFR) are associated with cardiovascular disease
the subset of patients with end-stage renal disease (ESRD)(CVD) in patients with end-stage renal disease (ESRD).
than there is in the general population.Methods. A cross-sectional sample of 459 patients with ESRD
on chronic dialysis was assessed to determine whether tHcy and A common variant of a key enzyme in homocysteine
the C677T mutation are associated with CVD prevalence in multi- metabolism, the C677T mutation (also known as the ther-
ple logistic regression. As CVD mortality is high, we examined molabile variant) of methylenetetrahydrofolate reduc-the relationship between homozygosity and duration of dialysis.
tase (MTHFR), located on chromosome 21, is emergingResults. Mean tHcy was higher in patients without a history
as a possible genetic contributor to hyperhomocysteine-of CVD (35.2mol/L vs. 30.4mol/L, P 0.02). In multivariate
models, CVD was negatively associated with tHcy and posi- mia and CVD. The C677T point mutation of MTHFR
tively associated with TT genotype, male gender, and body results in a valine substitution for alanine [2]. With two
mass index. Mean tHcy levels were higher among those with copies of this variant (TT), serum activity of MTHFR is
the TT genotype compared with those with the CC genotype reduced to 30%, while serum activity of heterozygoteswhen adjusted for age, folate, creatinine, and albumin (37.9
(CT) is 65% of that of wild-type (CC) individuals [2].mol/L vs. 31.9 mol/L, P 0.005). Among whites, the preva-
Epidemiologic evidence supports an influence of C677Tlence of the TT genotype was higher in those having undergone
less than one year of dialysis (P  0.002). genotype on homocysteine metabolism for those with
Conclusions. The C677T genotype of MTHFR is associated relatively reduced folate levels [3–5], and this is mildly
with CVD in ESRD and may be a more meaningful marker and less consistently so for the general population [3, 6].
than tHcy for abnormal homocysteine metabolism in ESRD. The C677T mutation also may influence tHcy levels inProspective data from ongoing clinical trials are needed to
ESRD, especially in those with low folate levels [7, 8].improve our understanding of these findings. Screening for this
The role of the C677T mutant allele in increasing thepolymorphism may help guide prevention measures.
risk for vascular disease was unconfirmed in large studies
[3, 9], a recent meta-analysis [6], and was not found in
a study of 545 Japanese hemodialysis patients [7]. WhileHyperhomocysteinemia is under intense investigation
it appears that the C677T mutation of the MTHFR geneas a readily modifiable risk factor for cardiovascular dis-
may influence tHcy levels, especially in folate depletion,ease (CVD) in the general population and in those with
its role in hyperhomocysteinemia and CVD is unclear.renal impairment. Despite homocysteine’s role in vascu-
Patients with ESRD have levels of tHcy that are threelar pathophysiology in vitro and animal studies, clinical
times those of the general population [10]. Despite a
strong, positive relationship between serum creatinine
and tHcy [11], the mechanism of hyperhomocysteinemiaKey words: end-stage renal disease, methylenetetrahydrofolate reduc-
in renal failure appears to operate through the inhibitorytase, C677T genotype, hyperhomocysteinemia, folate depletion, vascu-
lar pathophysiology, blood pressure, dialysis. effect of putative uremic factors on enzymes in the folate-
homocysteine pathway [12]. It appears to be unrelated toReceived for publication August 24, 2000
reduced renal clearance as renal failure progresses [13].and in revised form March 29, 2001
Accepted for publication April 10, 2001 Because patients with ESRD have a crude mortality rate
of 24%, half of which is due to CVD [14], improved 2001 by the International Society of Nephrology
1106
Wrone et al: Homocysteine and cardiovascular morbidity 1107
understanding of tHcy and cardiovascular risk may lead to for over-the-counter vitamin supplement intake. For those
on hemodialysis, the following were collected: vascularthe development of treatment and prevention strategies.
We undertook an investigation of tHcy and the C677T access history and predialysis and post-dialysis systolic
and diastolic blood pressure (averaged over 9 treatments).mutation of MTHFR in the pathogenesis of CVD. This
report is a cross-sectional analysis of baseline entry data In addition, the most recently monthly dialysis adequacy
parameters were collected for all hemodialysis subjects.from a randomized prospective clinical trial of tHcy re-
duction in ESRD patients. The questions addressed in Adequacy parameters included Kt/V, a unit-less measure
of dialysis dose, and normalized protein catabolic ratethis article are as follows: (1) Is tHcy associated with
CVD in this population? (2) What factors influence the (nPCR). This kinetic modeling was single-pool, variable-
volume urea using predialysis and post-dialysis blood ureatHcy level? (3) Is the C677T variant of MTHFR associ-
ated with elevated tHcy, CVD, and survival on dialysis? nitrogen (BUN) assessment. The predialysis blood sample
was taken prior to the initiation of dialysis and administra-
tion of saline or heparin. The post-dialysis sample was
METHODS
taken from the arterial port closest to the patient using
Study population the slow flow technique (within 15 to 30 seconds with the
blood flow rate decreased to between 50 to 100 mL/min).This analysis represents the findings of the baseline
entry exam to a clinical trial, after informed consent and
Biochemical assaysprior to initiation of any study procedures or treatments.
The clinical trial was a randomized, standard-therapy All patients had predialysis study blood samples drawn
in conjunction with routine monthly specimens. tHcycontrolled study of high-dose folic acid for the reduction
of tHcy with clinical outcomes as end points. We studied concentrations were determined by high-performance
liquid chromatography (HPLC) of serum specimens by459 prevalent patients with ESRD undergoing chronic
dialysis treatment (430 hemodialysis and 29 peritoneal Quest Diagnostics (San Diego, CA, USA). Normal val-
ues by this method are 2.8 to 13.5 mol/L. Serum folatedialysis) at 10 affiliated nonprofit outpatient units in
northern California from March 1998 to May 1999. Adult was determined using an ion capture assay that remains
linear up to 20 ng/mL. Specimens with levels higher thanpatients who were undergoing hemodialysis or peritoneal
dialysis and who were able to participate in the consent 20 ng/mL were diluted. The normal range for serum
folate was 3.1 to 12.4 ng/mL. Vitamin B12 determinationprocess were eligible for the study. Patients who were
undergoing intradialytic parenteral nutrition, anticipat- was performed using standard clinical diagnostic tech-
niques by Quest Diagnostics. The normal range for vita-ing a living-related kidney transplant, receiving an anti-
seizure medication, or were terminally ill were excluded min B12 was 200 to 1100 pg/mL. Total cholesterol, albu-
min, urea, creatinine, pre-albumin, phosphorus, glucose,from the study. A written consent was obtained from
every patient after a full explanation of the study, which and triglyceride determinations were performed at Satel-
lite Laboratory Services, Inc., as part of the routinewas approved by the Administrative Panel on Human
Subjects in Medical Research of Stanford University. At monthly care. Identification of the C677T translocation
was performed using HinfI digestion and polymerasethe time that these data were gathered, the participants
had not received instructions to change their pattern of chain reaction (PCR) amplification from specimens of
peripheral blood lymphocytes as described by Frosst etfolic acid or multivitamin use. CVD was defined as being
present if there was a history of coronary artery interven- al [2]. PCR analysis was performed in the Molecular
Diagnosis Laboratory (Department of Pathology, Stan-tion, myocardial infarction, stroke, transient ischemic
attack, carotid end-arterectomy, or other clinical evi- ford University Medical Center, Palo Alto, CA, USA).
dence of CVD, as documented in hospital discharge sum-
Statistical methodsmaries or history and physical examination upon admis-
sion to the dialysis unit. Correlations between continuous variables were tested
with Pearson’s correlation coefficient. Chi-square testsBaseline clinical variables were collected at the time
of enrollment. These included diabetes status; smoking and analysis of variance were used to test relationships
concerning dichotomous variables. The Student t test washistory; duration of renal replacement therapy; prescribed
medication use, including dose and formulation of all vita- used for testing involving means of distributions. The
distribution of genotypes was assessed for conformationmin supplements; height; and dry weight (the prescribed,
postdialysis weight). Race was assigned from one of the to the Hardy-Weinberg equilibrium by chi-square analy-
sis as described by Emery [15]. Logistic regression wasfollowing categories: African American, Asian/Pacific Is-
lander, other/multiracial, or white. Patients were assigned used to identify independent predictors of CVD and
multiple linear regression was used to identify indepen-a separate ethnic status that included Hispanic or non-
Hispanic. Patients from four facilities were further as- dent relationships to tHcy. All data analyses were per-
formed using the SAS Systems version 6.1.2 softwaresessed for compliance with prescribed vitamin use and
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Table 1. Characteristics of study cohort
No cardiovascular disease Cardiovascular disease
Variable N  303 N  156 P
Demographics
Age years 58.816.0 63.612.6 0.001
Male % 42.9 64.1 0.001
Race/ethnicity  whitea % 66.7 70.5 0.40
Diabetic % 44.2 48.1 0.43
Duration of dialysis years 3.94.7 3.54.0 0.28
Body mass index kg/m2 26.66.4 24.75.3 0.002
Current smokers % 9.9 12.8 0.34
Past smokers % 30.4 42.3 0.01
Laboratory assessments
Serum folate nmol/L 20.014.1 (302) 21.815.6 (155) 0.22
Vitamin B12 pg/mL 715635 (302) 644298 (153) 0.19
Serum creatinine mg/dL 9.13.2 8.72.7 0.18
Serum albumin mg/dL 3.970.36 4.000.31 0.43
Pre-albumin mg/dL 31.37.7 32.28.2 0.24
Serum cholesterol mg/dL 17842.4 17441.9 0.38
TT genotype C677T variant MTHFR % 9.2 19.9 0.001
CT genotype C677T variant MTHFR % 42.6 35.3 0.13
Homocysteine lmol/L 35.224.0 30.412.9 0.02
Homocysteineb lmol/L 34.6 31.5 0.0001
Hemodialysis patients, N  430
Systolic blood pressurec mm Hg 15721.0 15319.3 0.06
Diastolic blood pressurec mm Hg 80.512.5 76.311.0 0.0009
Kt/Vd N  428 1.550.47 1.630.51 0.10
NPCRe g/kg, N  428 0.930.23 1.000.30 0.01
The number of subjects is in parentheses.
a Includes both non-Hispanic and Hispanic whites
b Adjusted for age, gender, and body mass index
c Predialysis, averaged over 9 treatments
d Kt/V is a unit-less measure of dialysis dose
e NPCR is normalized protein catabolic rate
program. Results are reported as mean  SD, except phorus, and glucose were not significantly different. One
hundred fifty-six patients had at least one cardiovascularwhere otherwise indicated.
procedure or event, including coronary artery bypass graft,
percutaneous transluminal coronary angioplasty, previ-
RESULTS
ous myocardial infarction, stroke, or carotid endarterec-
Subjects tomy. These patients are listed by individual event: coro-
nary artery bypass graft (54), previous myocardialThe mean age of the patients (230 males and 229
females) was 60.4  15.1 years. The racial/ethnic groups infarction (54), percutaneous coronary intervention (24),
stroke (37), and carotid endarterectomy (9). There wererepresented were 186 non-Hispanic white, 137 Hispanic
(126 of whom were Hispanic-white), 71 Asian/Pacific Is- 50 patients with at least one limb or partial limb amputa-
tion. tHcy was higher in males than in females (34.9 landers, 54 African American, and 11 other/multiracial.
Etiology of ESRD was diabetes type I (5.4%), diabetes 25.0 vs. 32.2  16.0 mol/L, P  0.17), although this
was not a statistically significant finding. Diabetics andtype II (35.4%), hypertension/large vessel disease/cardiac
(24.6%), glomerulonephritis (18.1%), secondary glomer- nondiabetics had similar tHcy levels.
ulonephritis (3.1%), interstitial/pyelonephritis (5.2%),
Characteristics by C677T mutation ofcystic/hereditary/congenital (4.6%), neoplasms (0.4%),
MTHFR genotypemiscellaneous (2.0%), and etiology uncertain or un-
known (2.2%). There were 59 patients with two copies (TT) of the
allele, 184 with one copy (CT), and 216 with the wild-The clinical characteristics of the cohort with respect
to the presence of CVD are described in Table 1. Mean type allele (CC). This distribution did not vary signifi-
cantly from the expected frequencies (49.7 TT, 202.6tHcy was significantly higher in patients without a history
of CVD (35.2 mol/L  24.0) as compared with those CT, 206.7 CC) of these genotypes based on a Hardy-
Weinberg equilibrium (2  3.89, degrees of freedom 2,with a history of CVD (30.4 mol/L  12.9, P  0.02).
Patients with CVD were of older age, smaller size, and P  0.14). There were very few copies of the thermola-
bile variant in nonwhite ethnic groups. Three Asian pa-higher nPCR. The duration of dialysis, vitamin B12 levels,
folate levels, pre-albumin, cholesterol, creatinine, phos- tients, as well as one African American patient, were
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Table 2. Clinical characteristics by C677T variant of MTHFR
TT CT CC
N  59 N  184 N  216 P
Age years 63.613.4 61.214.5 59.015.8 0.08
Age initiation ESRD years 60.115.7 57.416.4 55.117.4 0.10
Age initiation ESRD years, non-whitea 48.219.6 (N4) 56.817.1 (N40) 53.317.0 (N103) 0.42
Male % 62.7d 53.3 44.0 0.02
Race/ethnicity  whitea % 93.2d 78.2d 52.3 0.0001
Diabetic % 55.9 45.7 42.6 0.19
Duration dialysis years 3.54.8 3.84.5 3.94.3 0.81
Serum folate nmol/L 20.512.1 20.314.1 20.915.8 (214) 0.93
Vitamin B12 pg/L 618319 (56) 658418 (183) 740674 (214) 0.18
Serum creatinine mg/dL 8.33.1d 8.72.7d 9.33.2 0.01
Serum albumin mg/dL 3.960.4 3.980.3 3.990.3 0.83
Homocysteine lmol/L 37.916.8 34.143.5 31.913.5 0.14
Homocysteineb lmol/L 39.4e 34.4 31.4 0.0001
Cardiovascular disease % 52.5df 29.9 32.4 0.005
Cardiovascular diseasec % 49.0df 29.0 34.0 0.0001
ESRD is end-stage renal disease.
a Includes both non-Hispanic and Hispanic whites
b Adjusted for age, folate, creatinine, and albumin
c Adjusted for age, race/ethnicity, and gender
d Comparison with CC genotype significant at the 0.05 level by Bonferroni t test for multiple comparisons
e Comparison with CC genotype significant at the 0.005 level by Bonferroni t test for multiple comparisons
f Comparison with CT genotype significant at the 0.05 level by Bonferroni t test for multiple comparisons
homozygous for the mutation. There were six patients
with the CT genotype in the other/multiracial group and
five with the CC genotype. Hispanics as a group had a
higher representation of heterozygotes and homozygotes
than non-Hispanic whites. TT genotype comprised 23.4%
for Hispanics and 12.4% for non-Hispanic whites (2 
9.0, degrees of freedom 2, P  0.01).
Table 2 shows the clinical characteristics of the three
genotypes. The genotypes were similar with respect to
age, age at initiation of dialysis, duration of dialysis, folate,
and albumin. When adjusted for age, folate, creatinine,
and albumin, tHcy levels were significantly higher in the
TT group than in the CC group (39.4 mol/L in TT vs.
31.4 mol/L in CC at the0.005 level by the Bonferroni
t test for multiple comparisons). The genotypes differed
Fig. 1. Relationship between low-folate status and total serum homo-with respect to creatinine and percentage of males. The
cysteine (tHcy) stratified by genotype. Low folate was defined as belowTT genotype had a significantly higher prevalence of the median folate level (less than 17.6 mg/mL; ). Mean tHcy levels
CVD than either the CT or CC genotypes (52.5 vs. 29.9 are shown with standard error bars for each genotype. There were no
significant differences in tHcy among the genotypes in the above-medianand 32.4%, respectively, P 0.05 by the Bonferroni t test
folate group (). There was an effect of genotype on tHcy in the belowfor multiple comparisons). This relationship persisted median folate group (P 0.01). This effect persisted when adjusting for
after adjustment for age, race, and gender. The effect of age, creatinine, and albumin. The asterisk refers to significant difference
compared with the CC genotype in the below median folate group atthe TT genotype under conditions of below median fo-
the 0.05 level using the Bonferroni analysis of multiple comparisons.late status is illustrated in Figure 1. The study group was
divided in two groups based on folate levels (above and
below the median level of 17.6 mg/L).
plement were at least partially compliant (taken at least
Concomitant vitamin and folate use once in past 2 weeks), and 18% of patients not prescribed
Of the 459 patients, 80% were prescribed a supple- a folic acid-containing supplement were taking at least
ment containing folic acid, vitamin B6, and vitamin B12. one folic acid-containing supplement. Brand name, dose,
At four facilities representing 206 patients, we obtained and actual dosing frequency were obtained on all 206,
further concomitant vitamin information. Of these 206, and the mean total daily amounts were as follows: folic
acid 0.67 mg, vitamin B6 7.27 mg, and vitamin B12 5.52 g.80% of patients prescribed a folic acid-containing sup-
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Table 3. Correlation of homocysteine with continuous variables
(Pearson correlation coefficients for homocysteine)
Variable Rho P
Age 0.20 0.0001
Duration of dialysis 0.12 0.009
Body mass index kg/m2 0.19 0.0001
Folate, serum, N  457 0.21 0.0001





Kt/V, N  428 0.18 0.0002
NPCR, N  428 0.13 0.008
Folic acid, daily intake, N  206 0.33 0.0001
Vitamin B6, daily intake, N  206 0.33 0.0001
Fig. 2. Proportion of study patients by dialysis year. Dialysis year isVitamin B12, daily intake, N  206 0.26 0.0002
the year-subgroup of duration of dialysis. The asterisk refers to those
Kt/V is a unit-less measure of dialysis dose and NPCR is normalized protein groups identified as statistically different from year 1 (P  0.0001,catabolic rate.
controlling for age, race/ethnicity, gender, and diabetes).
Table 4. Logistic regression for cardiovascular disease prevalence
tHcy (negatively), and the TT genotype in a model that
95% Confidence removed age, race, cholesterol, albumin, diabetes, CTinterval
genotype, past and current smoking, and pre-albumin
Predictor variables Odds ratioa Lower Upper P
by backward selection. In addition, a yes/no term for
Intercept — — — 0.0001 concomitant vitamin intake was examined and was elimi-Gender (male  0) 0.40 0.26 0.62 0.0001
nated by backward selection from models (Table 4).Body mass index 0.94 0.90 0.98 0.003
Blood pressureb 0.97 0.95 0.99 0.0009
TT versus not TT 2.39 1.29 4.44 0.006 Relationship of MTHFR status to duration of dialysis
tHcy 0.98 0.97 1.00 0.04
The mutant allele frequency and the percentage of
Age, race, cholesterol, albumin, diabetes, CT-genotype, past and current
homozygotes were lower in those with duration of dial-smoking, and prealbumin were removed by backward selection.
a For one-unit incremental increase ysis of greater than one year (Fig. 2). This was statisticallyb Predialysis diastolic blood pressure
significant for non-Hispanic whites (25% compared with
8%, P  0.002). Among Hispanics with less than one-
year duration of dialysis, the TT genotype prevalence
Prediction of tHcy was 36% compared with 20% for those with greater than
one-year duration of dialysis (P  0.13).Univariate analysis of tHcy is shown in Table 3, which
presents the Pearson correlation coefficients of several
clinical variables. tHcy had a strongly positive correlation DISCUSSION
to creatinine and albumin and a strongly negative corre-
In this cross-sectional analysis of 459 dialysis patients,lation to age, folate, and daily intake of folic acid, vitamin
patients with a history of CVD had lower levels of tHcyB6, and vitamin B12. There were milder associations be-
than those without a history of CVD. This negative rela-tween tHcy and duration of dialysis, body mass index,
tionship persisted in multivariate analysis when control-vitamin B12 level, and pre-albumin.
ling for predictors of CVD, such as age, gender, and bodyIn multiple linear models for prediction of tHcy values,
mass index. However, the TT genotype was associatedhomozygosity for the C677T mutation, albumin, creati-
with prevalent CVD, even after adjustment for othernine, and an interaction term for folate and genotype
cardiovascular risk factors, including tHcy, and was asso-were strong, independent predictors. Body mass index,
ciated with duration of dialysis in non-Hispanic whites.vitamin B12 level, and folate level were weaker indepen-
Consistent with other investigations in the general popu-dent predictors. Age, gender, and actual daily intake
lation and ESRD, an association of the TT genotype andamounts of folic acid, vitamin B6, and B12 dropped out
tHcy was found among those in the lower half of theof models.
folate distribution.
Cardiovascular disease There are several reasonable explanations for the in-
verse association between tHcy and CVD and for theThe presence of CVD was independently predicted
association of the TT genotype with CVD observed inby gender (female protective), body mass index (nega-
tively), predialysis diastolic blood pressure (negatively) this cross-sectional analysis. First, a single determination
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of tHcy in ESRD, as measured in a cross-sectional study, to CVD [18]. While in the univariate analyses in this
study tHcy correlated with serum albumin, pre-albumin,may not represent lifetime tHcy exposure. During the
years prior to the development of ESRD, tHcy was likely and body mass index, there was no evidence that those
with CVD possessed a worse nutritional status than thoselower than the tHcy measured after dialysis was initiated.
Historical tHcy determinations are required to assess the without CVD. Inflammatory markers were not measured
in our study. If nutritional or inflammatory status doesrelationship to evolving CVD. However, the presence
of genetic polymorphisms, such as the C677T variant of play a role in the reverse association between tHcy and
CVD prevalence, we were unable to detect it in thisMTHFR, remains constant over a lifespan and can sug-
gest a lifetime of abnormal homocysteine metabolism. cross-sectional analysis.
Fourth, the phenomenon of an established risk factorOur data support the association of the homozygous
C677T variant of MTHFR and CVD. This implies that in the general population having a markedly different if
not opposite pattern in ESRD is not unique to our data.C677T genotype may be a better predictor of CVD in
ESRD than a single measurement of tHcy. Blood pressure, body size, and serum cholesterol are
well-established factors in the general population associ-Second, methodological limitations constrain the in-
terpretation of findings from cross-sectional analyses. ated with increasing cardiovascular risk [19, 20], whereas
in ESRD, there is a dramatically different picture. BloodFor studies of ESRD patients, this is particularly relevant
due to survivor bias from high mortality rates. Survivor pressure tends to have a “U”-shaped relationship with
mortality [21], while body size and cholesterol have anbias can potentially exert a strong influence on both
cross-sectional studies and clinical trials during the inverse relationship [22, 23]. This does not mean that
the forces of vascular pathophysiology are different incourse of dialysis, especially when patients are enrolled
with varying degrees of duration of dialysis. Ideally, clini- ESRD, but suggests there are underlying factors respon-
sible for the apparent reversal of relationships observedcal studies include patients from the same duration of
dialysis cohort, that is, recent initiators and attempt to when traditional variables are analyzed in ESRD. For
example, in a hypothetical model adjusting for malnutri-control for differences in residual renal function. Survival
to the clinical state of ESRD may in and of itself impart tion, the direction of the relationship of cholesterol and
mortality reverses [24]. It is conceivable that cardiovas-a different risk profile, as patients with chronic renal
insufficiency (and possibly the most adverse homocys- cular risk factors, as we understand them in the general
population, behave quite differently in ESRD due toteine metabolism) succumb to CVD. Additional meth-
odologic explanations for reversal of association include reverse causation [24]. Similar relationships may apply
to tHcy as well, whereas a marker that remains constanterror of tHcy measurement and CVD assessment. Possi-
ble specimen collection errors include failure to spin over a lifespan, such as the TT genotype, would not
experience this relationship.within 30 minutes or a failure to refrigerate. This seems
unlikely, since the mean levels are very similar to other Fifth, should the observation that dialysis patients with
prevalent CVD have lower levels of tHcy than thosestudies. tHcy assessment was done using a commercial
HPLC assay that is well established. With respect to without a history of CVD represent a refutation of the
hypothesis that tHcy plays a role in vascular pathogene-using clinical records for the assessment of CVD, we are
likely overlooking cases of atherosclerotic disease in this sis? While this study is not designed to answer the ques-
tion, it can lend credence to the assertion that tHcypopulation as most patients would have pathologic find-
ings revealed by further clinical tests or autopsy. represents a marker for other factors that are important
in vascular pathophysiology, rather than a causativeThird, there may be a strong nutritional component
driving the relationship between tHcy and comorbidity agent. Not all epidemiologic studies in the general popu-
lation and clinical studies in ESRD have supported anin ESRD due to the influence of serum albumin and
dietary protein intake on tHcy levels. This observation association between homocysteine and CVD. Prospec-
tive case-cohort analyses from three large-scale commu-is supported by similar findings in a recent cross-sectional
study of 117 hemodialysis patients [16]. In that study, nity and population studies, The Atherosclerosis Risk
in Communities Study [25], a nine-year Finnish studytHcy levels were dependent on nutritional status, protein
intake, and serum albumin, and patients with CVD had [26], a report from the U.S. Physicians Health Study [27],
as well as a meta-analysis of 36 studies [6] have failedlower tHcy levels as well as a higher prevalence of malnu-
trition and hypoalbuminemia than those without CVD. to find an association. Cross-sectional studies in ESRD
have reported conflicting associations [10, 11, 28–30],Furthermore, tHcy rises during treatment of malnour-
ished patients with an amino acid-containing peritoneal and case-control studies may inflate an association by
selection of non-ESRD controls [31]. A study of 73dialysate (1.7 g methionine/day or half-normal intake)
[17]. The presence of chronic inflammation further com- ESRD patients followed for 17 months was only able to
adjust for one covariate at a time [32]. Another 17-monthplicates the relationship by suppressing serum albumin,
an important binding site for tHcy, and by contributing study of 167 patients with ESRD on dialysis found the
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relative risk for CVD to be 1.01 per 1 mol/L increase CVD. This description of this association is limited due
to factors such as survivor bias, confounding by malnutri-in tHcy, with a 95% confidence interval that included
1.00 [33]. Larger, prospective studies are needed in tion or inflammation as seen with other cardiovascular
risk factors in ESRD, or the possibility that tHcy is notESRD to address important questions about the causal
role of homocysteine and clinical trials are needed in a causative risk factor in ESRD. THcy levels obtained
after the onset of ESRD may not accurately representboth ESRD and the general population to establish tHcy
as a modifiable risk factor. the lifetime tHcy exposure and the C677T genotype may
be a more meaningful marker of abnormal homocysteinePrevious studies have shown that the prevalence of
the TT genotype remains stable across age groups in the metabolism in ESRD. Prospective data from ongoing
clinical trials are needed to improve our understandinggeneral population [34, 35], and that the superior survival
of African Americans and Asians compared with whites of this finding.
in the United States has yet to be fully explained [36, 37].
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